Back

Preclinical evaluation of a novel dual acting V1a/V2 vasopressin receptor antagonist by using a noninvasive cardiac output monitor

26 May 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 2 - Basic Science - Chronic Heart Failure – Pathophysiology and Mechanisms Experimental Heart Failure HFA Premium Access Heart Failure 2018

About the speaker

Photo
Doctor Thomas Mondritzki

Bayer AG, Wuppertal (Germany)

46 More presentations in this session

Presentation thumbnail
Increased expression of galectin-3 in the interstitium of left ventricular myocardium of dogs with chronic heart failure
Professor H. Sabbah (Detroit, US)
Abstract Slides
Presentation thumbnail
Necroptosis in post-ischemic heart failure: causality of cardiac dysfunction and remodeling?
Mr M. Lichy (Bratislava, SK)
Abstract
Presentation thumbnail
Genetic diagnosis in transthyretin cardiac amyloidosis - a single Polish centre experience
Doctor M. Gawor (Warsaw, PL)
Abstract
Presentation thumbnail
Differential endomyocardial expression of SGLT1 in idiopathic dilated cardiomyopathy patients with and without diabetes mellitus.
Doctor M. Vanderheyden (Aalst, BE)
Abstract
Presentation thumbnail
Decreased longitudinal left ventricular contraction after acute myocardial infarction in a porcine model revealing the opportunity for new treatments with mechanical circulatory support devices
Mr J. Berg (Lund, SE)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 2 - Basic Science - Chronic Heart Failure – Pathophysiology and Mechanisms

The Event

Event poster

Heart Failure 2018

26 May - 29 May 2018
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Presentation
Coronary microvascular dysfunction in heart failure: observations from the MICRO registry
thumbnail
Congress Session
Heart failure in the era of precision medicine: insights into pathophysiology and emerging treatments

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources